Immunology · Corticosteroid
The FDA's approval status for Tianjin Tianyao's Methylprednisolone ANDA204072 is significant as it enhances the company's competitive position in the corticosteroid market. This development necessitates a strategic assessment of the competitive landscape to mitigate potential market share loss for existing players.
Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.
Last run 7/26/2026, 6:31:21 AM
Assessment confidence: 68% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.
The FDA's approval status for Tianjin Tianyao's Methylprednisolone ANDA204072 is significant as it enhances the company's competitive position in the corticosteroid market. This development necessitates a strategic assessment of the competitive landscape to mitigate potential market share loss for existing players. Regulatory context from FDA (FDA AP — METHYLPREDNISOLONE SODIUM SUCCINATE (SUPPL)) supports the near-term read. Assessment grounded in 19 ranked evidence items (9 high-relevance).
Portfolio teams should assess the competitive landscape for corticosteroids and consider strategies to mitigate potential market share loss. The strongest clinical anchor is The Effect of Channa Striata and Curcuma Supplementation on Nutritional Status, Interleukin-6 Levels, and Quality of Life in Patients With Breast Cancer. In Immunology · Corticosteroid, 7 regulatory and 3 competitive items passed relevance filtering for Methylprednisolone.
The most relevant competitive pressure comes from FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for primary membranous nephropathy (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment. This approval status may enhance Tianjin Tianyao's position in the corticosteroid market, potentially impacting competitors with similar products.
Regulatory risk is concentrated around FDA AP — METHYLPREDNISOLONE SODIUM SUCCINATE (SUPPL) (FDA). Entity match (methylprednisolone); Regulatory pathway relevance (nda). The granted AP status indicates a favorable regulatory outlook, but final approval and market entry timelines will need to be monitored closely to assess full implications.
FDA AP — METHYLPREDNISOLONE SODIUM SUCCINATE (SUPPL)
FDAhigh relevance
Entity match (methylprednisolone); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — METHYLPREDNISOLONE SODIUM SUCCINATE (SUPPL)
FDAhigh relevance
Entity match (methylprednisolone); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — METHYLPREDNISOLONE SODIUM SUCCINATE (SUPPL)
FDAhigh relevance
Entity match (methylprednisolone); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — METHYLPREDNISOLONE (SUPPL)
FDAhigh relevance
Entity match (methylprednisolone); Regulatory pathway relevance (nda)
FDA document
View sourceThe Effect of Channa Striata and Curcuma Supplementation on Nutritional Status, Interleukin-6 Levels, and Quality of Life in Patients With Breast Cancer.
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceRelationship Between Clinical Status and Nerve Conduction Test Findings in Patients With Unilateral Hemiplegia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceHydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceVibratory Anesthesia on Pain Following Corticosteroid Injections
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceMenstrual Status, Anesthetic Consumption, and PONV
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceNeurophysiological Investigation of the Approach-avoidance Axis in OCD: Applications to Neuromodulation
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourcePhysical and Behavioral Traits of Overweight and Obese Adults
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceFDA grants Priority Review to Roche’s Gazyva/Gazyvaro for primary membranous nephropathy
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Grants Approval for Pitolisant Hydrochloride by Novitium Pharma
Humanexa Signalsmedium relevance
Moderate corpus alignment
Next-generation vaccine adjuvants: Integrating nanotechnology, systems immunology, and computational approaches for precision vaccinology.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceEffects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourcePrecedents · guidance
Loading regulatory precedents…
View full regulatory analysisCompetitors · threats
Loading competitive findings…
View full competitive analysisThe FDA's approval status for Tianjin Tianyao's Methylprednisolone ANDA204072 is significant as it enhances the company's competitive position in the corticosteroid market. This development necessitates a strategic assessment of the competitive landscape to mitigate potential market share loss for existing players.
The approval could lead to increased market share for Tianjin Tianyao, potentially affecting revenue streams of competitors with similar corticosteroid products.
The granted AP status indicates a favorable regulatory outlook, but final approval and market entry timelines will need to be monitored closely to assess full implications.
Monitor the final approval and market entry timeline for ANDA204072, as well as competitor responses.
Track for follow-up milestones; no immediate action required.